LUCIDITY Shows Clear Phase III Win For Amylyx’s Avexitide
In a Phase III study of Amylyx’s GLP-1 antagonist in post-bariatric hypoglycemia, avexitide reduced hypoglycemic events by 55% compared to placebo and met all secondary endpoints.
Scrip - August 18, 2026

FDA Weathers A Turbulent Year And A Half, Though Long-Term Damage Remains Unclear
The FDA has endured 18 months of instability and upheaval; and though it has met key review targets, the agency’s device center has not been unscathed. But experts differ on the degree of damage the agency has sustained and how effectively it can carry out its public health mandate going forward.
Medtech Insight - August 18, 2026

Enveda Moves Ahead To Address Post-GLP-1 Weight Loss Maintenance
The company is looking to address the problem of maintaining weight loss of patients who come off GLP-1 receptor agonists without the gastrointestinal side effects. Following positive Phase I results, ENV-308 will move into Phase II.
Scrip - August 18, 2026

IPF Pipeline’s Next Big Readout: Bristol’s Admilparant Pivotal Trial
In a disease with slow therapeutic progress, Boehringer Ingelheim’s Jascayd launch progress raises interest in Bristol Myers Squibb’s admilparant and other late-stage idiopathic pulmonary fibrosis candidates.
In Vivo - August 18, 2026

BioMarin Stays Focused On Genetically Driven Disease With Alesta Deal
Deal Snapshot: The rare disease specialist is acquiring a clinical-stage drug for hypophosphatasia caused by mutations in the ALPL gene.
Scrip - August 18, 2026

Lawsuit Paid And Patents Delisted Following Teva’s QVAR Inhaler Generics Settlement
A US judge has signed off on Teva's $35m settlement after allegedly delaying inhaler generics.
Generics Bulletin - August 18, 2026

China: Innovation, Deals And The New Rules Of Engagement
An Evaluate webinar shines the spotlight on the trends shaping the world’s fastest-moving market.
Scrip - August 18, 2026

Generic Drug User Fee Agreement Streamlines Meetings, Creates ‘Complex Issue’ Goal Extension
The GDUFA IV commitment letter will rename formal meetings and streamline its structure, as well as create a new goal date extension for complex regulatory issues.
Generics Bulletin - August 18, 2026

Stock Watch: Pharma Reaches For Substitutes As Organic Growth Founders
Investors expect earnings season to be about growth. This quarter, big pharma’s focus on cost-cutting and M&A revealed how deep the organic growth problem runs. Meanwhile, one merger rumor exposed the fragility beneath AstraZeneca’s bullish targets.
Scrip - August 18, 2026

GBMA Pushes For PBS Pricing Reform To Stave Off Australian Shortages
Australia’s generics and biosimilars body has called for PBS pricing, stockholding and regulatory reforms to make medicine supply more commercially sustainable and prevent shortages before they reach patients.
Generics Bulletin - August 18, 2026

Cook Medical Phishing, Baylor Genetics Breach Deepen Medtech Cybersecurity Concerns
Cook Medical and Baylor Genetics are the latest in a string of 2026 medtech cyber incidents that also hit Stryker, Intuitive, Medtronic, iRhythm and Abbott.
Medtech Insight - August 18, 2026

Insilico Medicine Launches Virtual Aging Cell Platform For Drug Discovery
Insilico's new platform combines AI, aging biology and virtual-cell modeling to support drug discovery.
Scrip - August 18, 2026

Expectations Vs. Reality: Formycon Faces Muted Stelara Biosimilar Momentum
Formycon confirmed its full-year revenue guidance of €60m–€70m, leaning on expected growth from the underperforming ustekinumab and far-from-launch but promising pembrolizumab biosimilars.
Generics Bulletin - August 18, 2026

Leo Strengthens Late-Stage Pipeline With Dersimelagon Buy
The Denmark-headquartered firm has acquired the rights to dersimelagon from Japan’s Tanabe Pharma, a potential competitor in the protoporphyria space to Clinuvel Pharmaceutical’s Scenesse.
Scrip - August 18, 2026

Strategic Intent: The Rise Of Mid-Cap Dealmakers
In this episode of Strategic Intent, Scrip’s Jessica Merrill unpacks how biopharma’s small-to-mid-cap players are stepping up as serious acquirers, using M&A to extend growth beyond their first commercial successes.
In Vivo - August 18, 2026

Sumitomo Hit By Second Gotham Broadside Over CiRA Claims
Japanese company faces fresh attack from US investment group questioning its relationship with a high-profile cell therapy research center and Nobel Laureate in Japan.
Scrip - August 18, 2026

US Cosmetics Industry Pushes Back on China’s Trade-Busting GMP Certificate Requirement
As US regulators develop a trade board to manage bilateral trade with China, the US cosmetics industry is looking for solutions to cosmetics regulatory differences between the countries.
HBW Insight - August 18, 2026